Zynex, Inc. Investors Urged to Seek Counsel Before Critical Deadline in Securities Class Action Suit Over Alleged False Statements and Misleading Disclosures.

Rosen Global Trial Counsel Encourages Zynex Inc. Investors to Secure Counsel Before Important Deadline

Chicago, IL - Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Zynex Inc. (NASDAQ: ZYXI) following the company's announcement that it will be conducting a global trial.

On April 12, 2022, Zynex Inc. announced that it will be conducting a global trial of its non-invasive, non-pharmacological, non-invasive blood glucose monitoring system, which is intended to be used by individuals with diabetes. The trial is expected to be conducted in multiple countries and will involve a large number of participants.

Rosen Law Firm is investigating whether Zynex Inc. and its officers and directors have made any false or misleading statements about the company's technology, the effectiveness of its blood glucose monitoring system, and the potential for the system to be used by individuals with diabetes.

Rosen Law Firm is advising investors who purchased Zynex Inc. securities to secure counsel before the important deadline that may be applicable to their rights. If you have purchased Zynex Inc. securities and would like to learn more about the investigation or have any questions about your rights, you are encouraged to contact the firm's attorneys at [phone number] or [email address]. You may also submit your contact information through the firm's website at [website URL].

Rosen Law Firm represents investors worldwide, focusing on securities litigation and investor rights. The firm has secured hundreds of millions of dollars for investors who have suffered losses due to corporate wrongdoing. The firm's attorneys have significant experience in securities litigation and have been recognized by various organizations for their expertise.

This notice is not a solicitation or an advertisement, nor is it intended to be one. The investigation is being conducted solely to determine whether Zynex Inc. and its officers and directors have made any false or misleading statements about the company's technology, the effectiveness of its blood glucose monitoring system, and the potential for the system to be used by individuals with diabetes. Any resulting claim will be made on behalf of the investors and not on behalf of the firm.